Meeder Asset Management’s Maravai LifeSciences MRVI Stock Holding History

Meeder Asset Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,206	Closed	-$30.9K	–	571
2023 Q1	$30.9K	Buy	+2,206	New	+$31.7K	﹤0.01%	462
2022 Q4	–	Sell	-338	Closed	-$9K	–	1521
2022 Q3	$9K	Sell	338 -196	-37%	-$4.92K	﹤0.01%	1363
2022 Q2	$15K	Buy	534 +1	+0.2%	+$32	﹤0.01%	1238
2022 Q1	$19K	Sell	533 -1,932	-78%	-$64.8K	﹤0.01%	1298
2021 Q4	$103K	Buy	+2,465	New	+$99.9K	0.01%	404

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Meeder Asset Management's MRVI Position: Q2 2023 in Review

Meeder Asset Management sold out of Maravai LifeSciences (MRVI) in Q2 2023, closing a stake of 2,206 shares — an estimated $30.9K sold.

Meeder Asset Management first reported a position in MRVI in Q4 2021 and held it in 5 quarters. The position peaked at $103K in Q4 2021. 221 funds tracked by Wall St. Rank hold MRVI as of Q2 2023.

Meeder Asset Management reported no remaining Maravai LifeSciences position as of Q2 2023 after selling out during the quarter.
Meeder Asset Management sold 2,206 Maravai LifeSciences shares in Q2 2023, an estimated $30.9K.
Meeder Asset Management first reported a position in Maravai LifeSciences in Q4 2021 and held it in 5 quarters.
Meeder Asset Management's Maravai LifeSciences position peaked at $103K in Q4 2021.
221 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2023.

Based on Meeder Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.